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 Imagine this: you wake up one morning, and it hits you. Today is going to be far worse 
than yesterday. The sound of bone on bone grinding is not just in your head anymore. You can 
hear your knee crack and cry out as you struggle to get out of bed. Once you manage to thrust 
yourself to a standing position, you become dizzy. Bam! Now you’ve hit the ground. You just 
hope that you haven’t broken another bone. Your family hears you fall and comes running. You 
fake a smile and say that you’re okay. Deep down you know you’re not though. You can barely 
move. Your knee is swollen, and you have no muscle mass. You look at yourself in the mirror 
ashamed. You were the captain of the hockey team and always had dreams of becoming a 
professional. You used to love going to work and going to the gym with your friends. Now all 
you can do is sit at home. You barely recognize that person staring back at you in the mirror. 
You are not in shape. You have put on a lot of weight. Most importantly, you are miserable, and 
you are told there is nothing you can do except take medications and wait. You are too young for 
a total knee replacement. You start to feel hopeless.  
 This hopelessness is the everyday feeling of Julia*1. In high school, Julia tore her 
meniscus during a hockey game. She received a surgery in which the entire meniscus was 
removed in order to repair it. The job of the meniscus is to protect the articular cartilage of the 
knee. Because of her exposed cartilage, Julia had an increased risk of developing osteoarthritis 
after this injury, but her love of hockey was too great to give up. She continued to push her knee, 
so that she could play hockey at a Division 1 college. She now cannot exercise. She can barely 
walk without excruciating pain. Julia wants to fix her condition, but she doesn't know how. She 
is worried about potential side effects caused by taking medications for too long.  
 
1 *Individuals referenced are not real patients 
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Henry* lives nearby and also struggles with osteoarthritis. His struggle is different 
though. Henry is 66 years old and has always been a bigger man. He started experiencing knee 
pain about 20 years ago. His parents both had two knee replacements, so he assumed knee pain 
just came with age. His friends told him to try to lose weight, but Henry always complained. 
Henry knew exercising made his knees hurt more. To try to ease his pain, Henry started taking 
anti-inflammatory medications 15 years ago. He hoped that he could continue to stay on these 
medications for longer, but that has not been the case. Henry had an ulcer potentially caused by 
the medications last year. Since, he has started to notice the medication does not seem to be 
working as well. Henry now has a very difficult time getting up out of chairs to stand because of 
the pain. His knee is noticeably swollen and always feels warm in the joint. Henry’s knee has 
begun to creak when he walks which has become embarrassing for him.  His doctor also informs 
him that with his current weight, he is at an increased risk for cardiovascular complications. 
Henry and his doctor have begun to discuss a total knee replacement in his near future.  
Though both Julia and Henry have osteoarthritis, they have different needs. The two of 
them are told about an experimental procedure that could potentially improve their quality of 
life. It is a new therapy using injections of stem cells which are cells that can differentiate into 
any bodily tissue. It has not been approved for large scale usage yet, but a hospital nearby is 
accepting individuals willing to try it. Should Henry and Julia try it?  
The purpose of this project was to investigate the possibility of stem cell therapy 
becoming a prominent treatment for osteoarthritis as an alternative to the use of anti-
inflammatory medications before a total knee replacement. Stem cell therapy is a rapidly 
growing technique for treating diseases. For about 30 years, stem cell therapy has been used to 
treat blood and bone marrow disorders, leukemia, and immune disorders (University of Utah, 
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2014).  In particular, I think that stem cell therapy would be most useful for those individuals 
such as Julia who are too young for a total knee replacement but cannot continue to live with the 
pain of osteoarthritis. These individuals often fall into what is known as the treatment gap. The 
treatment gap exists because there is no known treatment for these younger individuals who still 
struggle every day with osteoarthritis. Treatment for osteoarthritis needs to be individualized, 
and I was interested in discovering whether stem cell therapy would be beneficial for both, one, 
or neither Julia and Henry. I have researched the treatment, the cost, the side effects, and the 
potential benefits of using stem cell therapy. Stem cell therapy for osteoarthritis could transform 
the lives of individuals such as Julia and Henry by relieving their suffering and giving them a 
second chance at a relatively risk-free active lifestyle. Stem cell therapy could lower costs and  
limit the number of surgeons and physical therapists needed to care for osteoarthritis patients 
alone.  
In this thesis, I introduce the disease of osteoarthritis and the popular treatments in use for 
patients today. I will pay specific attention to the knee replacement because it is the most 
common treatment for end stage osteoarthritis. Finally, I will look at the up and coming stem cell 
therapy for osteoarthritis of the knee through an examination of case studies currently being run 
around the world. To conclude, I will suggest which treatment appears to be the best treatment 









In our society, the elderly and obese populations are increasing steadily. These 
populations are the most at risk for osteoarthritis. Osteoarthritis is now the most common form of 
joint disease worldwide. In the United States, about 12 percent of the population struggle each 
day with pain caused from osteoarthritis (Zhang et al, 2010). It is estimated that 1 in 10 
Canadians over the age of 15 struggle with osteoarthritis (Khan, et al, 2018). Osteoarthritis is 
often referred to as a “wear and tear” disease though some forms can be caused by genetics. 
Phrases such as these implicate that there is no modification that can be done to cure 
osteoarthritis. Osteoarthritis remains the most common reason for patients to undergo total joint 
replacements (Khan et al, 2018).  
 The cause of osteoarthritis remained a mystery for a long time until the discovery of 
degrading enzymes in cartilage in the 1980s (Vincent et al, 2018). Degrading enzymes can be 
enhanced by damage to cartilage caused by a destabilizing injury that leaves an upregulation of 
matrix metallopeptidase (MMP), an enzyme involved in normal cartilage turnover. Osteoarthritis 
is characterized by a loss of articular cartilage which covers the end of bones (Figure 1). The loss 
of cartilage occurs originally at the articulating surface or adjoining surface of the joint then 
spreads through the bony matrix or surface of the bone until it reaches the subchondral bone or 
the layer of bone directly below the cartilage. Cartilage is made up of cells called chondrocytes. 
These cells are responsible for maintaining the bony matrix, but they are also the cells which 
synthesize degrading enzymes in cartilage. Changes in the tissue caused by loss of cartilage 
include patchy loss of aggrecan which is a protein that is responsible for the load-bearing 
property of cartilage, clustering of chondrocytes, and bony expansion of the joint with 
osteophyte or bony spur formation due to increased stress on the joint. Severe joint pain results 
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because as articular cartilage is damaged, it produces factors such as nerve growth factor. Nerve 
growth factor sensitizes local pain fibers which leads to chronic pain (Vincent et al, 2018).  
Several key symptoms determine diagnosis of osteoarthritis. Osteoarthritis includes 
severe joint pain and functional limitation of the joint. The development of symptoms can be 
acute and can affect one or more joints. Joint pain can either involve pain only during weight 
bearing periods or it can be persistent. Osteoarthritis causes the affected joints to be swollen. 
Muscle wasting and joint deformity as well as restricted range of motion and joint crepitus or 
bone cracking are often noted in individuals with osteoarthritis.  X-rays are often used to 
determine the severity of osteoarthritis. X-rays show the presence of osteophytes around the 
joint. The Kellgren-Lawrence scale is used to diagnose osteoarthritis in X-rays (Figure 2). A 
rating of 0 is a normal joint whereas a rating of 4 shows severe joint gap narrowing indicating the 
end stage of the disease (Vincent et al, 2018).  
Unfortunately, there are several external factors which can put people at risk for 
osteoarthritis. The first risk factor is mechanical load. Mechanical load is defined as the total 
load placed on a joint. There are two circumstances of abnormal load which can cause damage. 
The first is placing abnormal load on an undamaged joint. This is the case of an obese individual. 
In addition, adipocytes, which are cells that make up fat tissue, are known to secrete 
inflammatory cytokines or immune signaling molecules that can cause cartilage matrix 
degradation (Vincent et al, 2018). The second is placing normal load on a joint that has lost its 
protective mechanisms for joint movement. Either of these circumstances cause abnormal stress 
and damage to the joint which can result in the development of osteoarthritis. It has been found 
that young athletes who sustained knee joint injuries such as anterior cruciate ligament (ACL) 
tears have an increased risk of osteoarthritis (Vincent et al, 2018). Individuals who work in 
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occupations in which their joints are repetitively damaged in low impact injuries are also often at 
higher risk for osteoarthritis (Khan et al, 2018). Both of these injuries cause the joint to 
experience abnormal load because the protective mechanisms of joint motion such as the 
ligaments have been damaged.  
Two additional risk factors are age and genetics. On average, individuals over the age of 
50 develop symptoms of osteoarthritis (Anderson et al, 2010). Aged joints are more likely to 
experience mechanical failure due to loss of muscle strength which can cause an abnormal gait. 
Cartilage matrix synthesis is reduced while degradative pathways are increased as an individual 
ages (Vincent et al, 2018). The combination of these two events leaves older cartilage prone to 
degradation. As for genetics, twin studies have found that heritability in osteoarthritis is about 
60% meaning that genes play a large role in determining if an individual will have osteoarthritis.  
(Vincent et al, 2018). It has been found that osteoarthritis is polygenic (Chapman et al, 2012). 
This means that the disease is increased by changes in several different genes, so the risk of each 
individual gene is relatively small.  
 
Treatment Options 
 Treatment for osteoarthritis depends on the severity of the disease as well as on the 
individual being treated. Treatments are divided into three main categories- noninvasive 
treatments, injectable therapies, and surgical treatments. The noninvasive treatments are the first 
treatments used for individuals trying to manage the onset of osteoarthritis. The first noninvasive 
treatment is weight loss. Studies have shown that every kilogram of weight loss correlates to a 
quadruple decrease in forces across the knee (Khan et al, 2018). It is recommended that 
individuals do low-impact aerobic exercise such as swimming to promote weight loss as well as 
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cardiovascular health while also limiting damage to injured joints. Knee bracing is another less 
well known noninvasive treatment option. Knee bracing is not often used due to the limited 
quantity of evidence showing that it is beneficial. Physical therapy is another noninvasive 
treatment which can help to strengthen the quadriceps muscles. Strengthened quadriceps reduce 
load and direct force applied to the knee during movement so that stress is minimized (Fransen et 
al, 2015). The use of oral or topical anti-inflammatory medications (NSAIDs) is the last and 
most popular noninvasive treatment. It has been found that 65% of osteoarthritis patients in the 
United States are prescribed a nonsteroidal anti-inflammatory medication with diclofenac (150 
mg/day) being the most effective (da Costa et al, 2017). Oral medications have the fourfold risk 
increase of upper gastrointestinal bleeding. Topical nonsteroidal anti-inflammatory drugs are 
becoming more common for treatment of osteoarthritis. The most popular topical drugs are 
diclofenac and ketoprofen (Sardana et al, 2017). These drugs work by reducing hormones that 
cause pain and inflammation in the body. Both drugs, however, have side effects of dizziness, 
vomiting, increased blood pressure, swelling in arms or legs, and in more severe cases, ulcers 
and gastrointestinal bleeding (da Costa et el, 2017).  
 Injectable therapies and surgical therapies are used only if noninvasive treatments prove 
fruitless.  There are three types of injectable therapies. The first injectable therapy is 
viscosupplementation which injects a thick liquid into the knee joint space between the cartilage 
(Figure 1). Viscosupplementation adds viscoelasticity and shock absorption to synovial fluid, 
located in the knee joint space, which helps to maintain smooth joint movement and contains 
both anti-inflammatory and chondroprotective properties (Bellamy et al, 2006). There are several 
different formulas and dosing techniques so that each treatment program can be chosen for the 
individual being treated. The second type of injectable therapy is corticosteroids which are anti-
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inflammatory drugs. It has been found that these injections result in short-term pain 
improvement, but the effects decrease with long-term use (Khan et al, 2018). The last type of 
injectable therapy is known as combination therapy. Combination therapy is the simultaneous 
injection of more than one of the above injectable therapies to improve osteoarthritic pain (Khan 
et al, 2018).  
Surgical therapies are the last “option” for individuals struggling with osteoarthritis. 
Many individuals with end stage osteoarthritis opt for surgery because the pain is too much to 
live with. The first type of surgery is known as tibial osteotomy. A tibial osteotomy reshapes the 
tibia to realign the knee. The procedure is used to either delay or to avoid a total knee 
replacement. It also allows the individual to remain active by preserving joint mechanics 
(Niinimaki et al, 2012). A study done between 1987 and 2008 found joint survivorship of 89% at 
5 years and 73% at 10 years after individuals had a tibial osteotomy (Niinimaki et al, 2012).  
The second surgical treatment is a unicompartmental knee arthroplasty also known as a 
partial knee replacement. This surgery can only be performed for cases of monocompartmental 
osteoarthritis where only one joint surface is damaged. Candidates for this surgery are at 
significant risk for revision surgery if they are younger than 55 years old due to higher demands 
on knee function and longer life expectancy (W-Dahl et al, 2010). It is easier to return to an 
active lifestyle after a partial knee replacement as opposed to a total knee replacement. The 
percent of return to sport after this surgery was 75% to greater than 100%, meaning that more 
individuals lived active lifestyles after surgery than before (W-Dahl et al, 2010).  
The final surgical option is a total knee replacement which is only done after all other 
options have been exhausted due to the surgery’s high cost, potential for revision surgery or 
infection, and minimal increase in quality of life. Total knee replacement is effective in 
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improving function and limiting pain. The implant survival depends on the individual’s activity 
level, bone quality and age, and fixation method of the implant (Losina et al, 2012). Total knee 
replacements are not recommended for patients younger than 60, however. Knee replacements 
tend to only last about 20 years, so younger patients would potentially need revision surgery later 
in life. Because total knee replacements are the most popular surgical option today, they are 
being compared to the new stem cell therapy. To accomplish this, knee replacements will be 



















 There are more than 600,000 total knee replacements done every year in the United 
States (Ortho Info). The average patient is normally between the age of 50-80, and there is no 
weight limit. The demand for total knee replacements is projected to increase 601% by the year 
2030 due to increasing obesity rates and baby boomers headed into retirement (Turner 2011). 
Total knee replacements become the only option after pain medications and supportive walking 
devices such as bracing no longer aid the individual enough to keep them moving.  
 The price of a knee replacement in the United States is averaged at $49,500 (BWH, 
2019). This includes the number of days in the hospital, the length of time spent in the operating 
room, and the type of implant. Inpatient charges are charges acquired while an individual is in 
the hospital. Inpatient charges typically add about $7,500. There are also outpatient costs when 
the individual is not in the hospital such as extended physical therapy and follow-up 
appointments. Depending on the insurance coverage, the average individual is often paying 
hundreds to thousands of dollars out of pocket. There are also additional costs to ensure that the 
individual’s house is accessible for the person. The individual may not be able to work for 
several weeks, so it is important to note that loss in salary if the individual does not qualify for 
disability insurance (BWH, 2019). One option to save money is to consider having the surgery 
performed in another country, but it is important to make sure the surgeon is accredited by the 







 Before receiving a total knee replacement, an orthopedic examination must be performed 
by the surgeon. The surgeon will assess the individual’s medical history, knee function, x-rays, 
and any other tests needed such as an MRI. The individual should also prep for post-surgery. 
They will be unable to take care of themselves for a little while, so each patient will need 
someone to care for them until they can walk with crutches. Some household modifications 
might need to be made. These include adding safely rails and seats to the stairways and showers 
(AAOS, 2019). One might also consider living on the lowest level of their home.  
Depending on the individual’s past medical history, anesthesia is chosen. Either general 
anesthesia or local anesthesia from the waist down is chosen. During a total knee replacement, 
the joint is resurfaced. The areas of cartilage which were damaged are removed from the knee 
joint along with a thin layer of bone. The removed areas are replaced with metal devices. A 
plastic spacer is placed between the metal components to reduce friction for a smooth gliding 
surface (AAOS, 2019). In some cases, the patella is also resurfaced and replaced with a metal 
button. The whole procedure takes about one to two hours. The procedure is done with the 
patient lying in a supine position with their knees flexed. A 6-inch cut is made down the midline 
of the knee joint before moving the tendons and muscles aside to access the joint (Turner, 2011).  
 There are serious complications in less than 2% of the people who receive knee 
replacements (AAOS, 2019). These complications can include infections of the wound area, 







 After the surgery, the individual remains in the hospital for a few days. The pain is 
managed using either opioids or non-steroidal anti-inflammatory drugs (NSAIDs). The 
individual must also do some blood clot prevention such as moving their ankle and foot or 
wearing compression stockings. Physical therapy also begins the day after surgery. The first step 
is often a continuous passive motion machine which helps to move the leg and evaluate it, which 
prevents stiffness (BWH, 2019). By the time one is discharged from the hospital, they must be 
able to walk 25 feet as well as climb and descend stairs, get in and out of bed using a cane, and 
bend their knee to 90 degrees (BWH, 2019). The physical therapy process after a total knee 
replacement is an extensive one. The ultimate goals by the sixth week after surgery include 
decreased swelling and increased range of motion, walking about half a mile, and being able to 
resume everyday activities and chores. The next check point is week eleven. By this point, the 
individual typically can resume driving and other recreational activities such as walking long 
distances or swimming. Some sample physical therapy exercises at this point include knee bends, 
single-leg balancing, and hip abductions (BWH, 2019). Full recovery from a total replacement 
can take up to one year. To be considered fully recovered one must be pain free and have 115 
degrees of movement in their knee.  
Outcomes 
 More than 90% of people who receive a knee replacement experience significant 
reduction in pain and increased ability to perform activities of daily living (AAOS, 2019). It is 
important to know that there should be no high intensity exercises after a knee replacement. The 
individual should not run, jog, or jump because it will increase the rate of deterioration of the 
plastic spacer causing the knee to become painful again. The knee that received the replacement 
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will not likely gain full range of motion (Turner 2011). The new knee is also prone to a clicking 
sound or feeling after surgery which should diminish after time. Currently, about 90% of all knee 
replacements last at least 15 years with proper care. On the other side, one third of those who 
receive a knee replacement continue to live in some pain (AAOS, 2019). This is especially true 
for younger people who have received knee replacements.  
If the arthritis is not extreme enough, the knee replacement should not be done because it 
does not increase the individual’s quality of life. Today, more knee replacements are being done 
than are properly prescribed. Younger individuals can outlive their knee replacement. The 
replacement is extremely painful when it wears out and a second surgery is much riskier as bones 
can break while removing the original metal device. Other methods of treatment such as stem 














Stem Cell Therapy  
There are several types of stem cells in the human body. All stem cells can divide to form 
more stem cells and also can differentiate to form other types of tissues (ISSCR, 2019). The 
types of stem cells differ in where they are located and when in life they appear. The most well-
known type of stem cell is the embryonic stem cell. Embryonic stem cells are found inside of the 
blastocyst which is a ball of cells formed 4 days after conception (ISSCR, 2019). Embryonic 
stem cells are pluripotent meaning they can become any type of tissue in the body which makes 
them very useful for medicine and research. There are ethical problems with using embryonic 
stem cells as an unborn fetus must be used for research. This creates divisions among people due 
to conflicting consciences of when a fetus becomes a child. Induced pluripotent stem cells are a 
lab created stem cell. These cells are created in a lab by converting somatic or body cells into a 
cell that behaves like an embryonic stem cell (ISSCR, 2019). These cells are not exactly like 
embryonic stem cells, but they are very useful for testing new drugs for treatments without 
causing any ethical battles. Tissue-specific stem cells are another stem cell found in the body. 
These cells are like differentiated embryonic stem cells because they are more specialized. These 
cells can only become cells for the specific tissue in which they live, so they are for replacing 
damaged cells in these regions (ISSCR, 2019). The last type of stem cell is the mesenchymal 
stem cell (MSC). These cells come from the stroma which is connective tissue surrounding other 
tissues. MSCs from bone marrow can make bone, cartilage, and fat cells, but scientists are not 
certain if these cells are truly stem cells because they are multipotent meaning they cannot form 
every type of tissue in the body (ISSCR, 2019).  
Recently, stem cells were speculated to be potentially effective in treating osteoarthritis. 
Stem cells used for these procedures would be harvested from individuals’ bone marrow or 
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adipose tissue. Specific stem cells called mesenchymal stem cells or medicinal signaling cells are 
thought to be able to treat osteoarthritis. Mesenchymal stem cells can sense their environment 
and secrete large quantities of signaling molecules as a response (Lopa et al, 2018). The actual 
process of how mesenchymal stem cells repair joint issue is unknown. Recently, studies have 
found that mesenchymal stem cell derived extracellular vesicles (EVs) protect cartilage against 
osteoarthritis and promote cartilage repair (De Bari et al, 2018). EVs are membrane enclosed 
particles which are released from mesenchymal stem cells. They contain biologically active 
signaling molecules. These cells can bind to target cells to activate intracellular signaling from 
the plasma membrane for cartilage repair (De Bari et al, 2018).  Mesenchymal stem cells are 
fibroblast-like cells which can form colonies from a single cell. They can also form several 
different skeletal tissues (van der Kraan, 2013).  
 There are different types of mesenchymal stem cells that can be harvested from the body 
and have been used for various clinical trials. Mesenchymal stem cells are in bone marrow and 
adipose tissue. These MSCs from different locations are theorized to be the same type of cells, 
but further research might prove otherwise. The first type is bone marrow derived mesenchymal 
stem cells. In one case study, a 47-year-old woman with severe osteoarthritis received treatment 
using bone marrow derived mesenchymal stem cells. The woman received 3.6 x 107 cells in a 
transplant to her knee joint. After 6 months, the MRI revealed that the cartilage covering the 
distal condyle of the femur and proximal part of the tibia had increased. The woman also 
experienced less pain, more function of the knee, and increased walking distance without any 
negative effects (Mehrabani et al, 2016).  
The second type of MSC is bone marrow aspirate concentrate which is made from fluid 
taken from bone marrow. Recent studies have found significant pain reduction and 
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improvements in function of the knee joint after 12 months of injection with bone marrow 
aspirate concentrate (Lopa et al, 2018). The third type is stromal vascular fraction from adipose 
tissue. Stromal vascular fraction includes MSCs along with fibroblasts and white blood cells.  
Clinical Trials 
A trial done by researchers at Monash University, registered both in Australia and New 
Zealand, looked at whether the number of injections of stem cell therapies for treating 
osteoarthritis affected the results seen in patients (Freitag et al, 2019). There were 30 participants 
with grade two or three osteoarthritis for which conservative treatment of anti-inflammatory 
medication was ineffective. The participants were either placed in a control group with no 
injection, received one injection, or received two injections (Freitag et al, 2019). The stem cells 
were taken from adipose tissue of the abdominal area. The cells were cultured and harvested to 
make a cell pellet. The cell pellet was suspended in saline to make the injection. Local anesthetic 
was injected above the joint capsule before the injection. The injection was put into the intra-
articular knee space using ultrasound for placement guidance (Freitag et al, 2019). Participants 
were told to use crutches for four weeks and given quadricep activation exercises. Pain was 
measured using the Numeric Pain Rating Scale, the Knee Injury and Osteoarthritis Outcome 
Score, and the Western Ontario and McMaster Universities Osteoarthritis Index. The Numeric 
Pain Rating Scale asks patients to rate their average pain from 0-10. The Knee Injury and 
Osteoarthritis Outcome Score measures quality of life and focuses on pain improvement, 
symptoms, activities of daily living, and use of sport for recreation. The Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) assesses pain, stiffness, and physical function 
of the knee. It was found that pain significantly decreased in both injection groups compared to 
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the control group (Freitag et al, 2019). Quality of life also increased in both injection groups 
(Figure 3).   
After MRI investigation, the two-injection group was the only group to have less 
cartilage loss and no osteocyte formation (Freitage et al, 2019). The control group and one 
injection group saw about 50% of participants experiencing osteocyte formation. Many of the 
participants experienced swelling after their injection, with two participants having swelling for 
four weeks. The researchers concluded that two injections six months apart were better than the 
singular injection due to the disease stabilization with two injections (Freitage et al, 2019). This 
means that the osteoarthritis did not progress with two injections, but it also did not heal 
completely. These results suggest that stem cells are more supportive such as reducing swelling 
rather than directly becoming chondrocytes. One strength of this study was that it showed that 
multiple injections of adipose derived stem cells are safe and effective for treating osteoarthritis. 
The study did have a weakness, though, being that none of the participants were blinded to their 
group. There could have been a placebo effect working against the conclusion of the 
questionnaires. The placebo effect is shown because the control group initially increased their 
WOMAC score even though they were not injected. The MRI analysis did help to correct some 
placebo effect because it had to either show disease progression or not compared to baseline 
MRI.  
A recent study was done under the Japanese Act on the Safety of Regenerative Medicine 
in which 13 participants with either Grade III or IV osteoarthritis received stromal vascular 
fraction therapy for their knee osteoarthritis (Yokota et al, 2017). The cells were harvested using 
liposuction of the lower abdomen. Each knee was injected with 3 x 107 stromal vascular fraction 
cells. The patients did restricted physical therapy in which they aimed to perform 100 “bend and 
21 
 
stretch” exercises the day of the injection and the day after the injection. The patients received 
oral pain relief medication for three days. The outcomes of the patients were accessed using the 
VAS for pain, the Japanese Knee Osteoarthritis Measure, and the Western Ontario and 
McMaster Universities Osteoarthritis Index. All of the patients had improved by about 30% over 
baseline measurements 1 month after the procedure which were sustained at the 6-month 
reevaluation (Yokota et al, 2017). There were no serious side effects for any participant during 
the procedure. There was some pain and swelling around the injection site for a few days. One 
important strength of this study is that the it is the only case study that is approved under a 
national act. The Japanese Act on the Safety of Regenerative Medicine was passed in November 
2014 to set standards for the use of stem cells in medical clinics (Yokota el al, 2017). These 
standardization laws for cell culture and processing are important for the use of stem cells 
because it is difficult to ensure each patient receives the exact same treatment because each 
person’s cells are different. 
 In the first Canadian mesenchymal stem cell clinical trial, the question of MSC dosage 
was investigated in twelve participants with severe osteoarthritis of the knee for whom 
conservative nonsurgical treatments such as anti-inflammatory medications had been ineffective 
(Chahal et al, 2019). The stem cells used came from bone marrow concentrate in the superior 
iliac spine. The superior iliac spine contains the most bone marrow in an adult body. To create 
the stem cell injection, the bone marrow was centrifuged to separate the stem cells (Chahal et al, 
2019). Next, the stem cells were cultured for about 30 days. The stem cells were harvested to 
make the injection. The other cells were analyzed for different types of proteins to see if all stem 
cells would be similar in each participant. The results used both the Knee Injury and 
Osteoarthritis Outcome Score and the Western Ontario and McMaster Universities Osteoarthritis 
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Index to access joint function and quality of life. MRI images were used to evaluate the cartilage 
before the injection and both 6 and 12 months after the injection. Four patients had local adverse 
effects after the injection of swelling around the site.  
There was a decrease in pain and symptoms as well as an increase in quality of life seen 
in the patients of all three doses, but the patients in the highest dosage saw the most consistent 
changes (Figure 4). There were no morphological changes in cartilage 12 months after stem cell 
injection. This could be because the study chose to include severe osteoarthritis (Stage IV) 
whereas other studies which saw cartilage changes did not. Cartilage cationic biomarkers which 
indicate disease progression decreased in the two higher doses. Synovial fluid showed a 
significant increase in anti-inflammatory and angiogenic biomarkers showing some change 
taking place in the site (Chahal et al, 2019). These results suggest that the larger dose of 50 
million stem cells might be more beneficial than the smaller doses of 1 million or 10 million 
cells. One strength of these results could be that the biomarkers of osteoarthritis such as 
increased macrophages decreased with the larger dose of stem cells. This indicates a potential 
mechanism by which stem cells reduce symptoms of osteoarthritis. Stem cells might reduce the 
number of macrophages by transforming them into inflammation resolving cells instead (Chahal 
et al, 2019). The impact of this study is weakened by its relatively small sample size that only 
included those with advanced osteoarthritis.  
 A new clinical study is starting in the United States at Emory University. This clinical 
trial compares injections of corticosteroids with different types of stem cell therapies. The three 
types of stem cell therapies are bone marrow concentrate stem cells, adipose tissue stem cells, 
and umbilical cord stem cells (Boden, 2019). In the study, each participant will randomly be 
given either a corticosteroid injection or a single type of stem cell therapy injection. The study is 
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recruiting participants between 40 and 70 who have osteoarthritis in one knee that is between 
Grades II and IV (Figure 2) (Boden, 2019). All subjects will have stem cells taken for both bone 
marrow concentrate and adipose tissue stem cells to ensure that the study is blinded. The 
participant will then rate their pain level, their osteoarthritis outcome score, their quality of life, 
and mental health domains at interval points throughout a year (Boden, 2019). Pain will be 
measured using the Visual Analog Pain Scale which asks the participant to draw a perpendicular 
line at the location that best describes their pain intensity and the Knee Injury and Osteoarthritis 
Outcome Score. Quality of Life will be measured by the EuroQuality of Life which has 
participants rate their experience with mobility, self-care, usual activities, pain, and anxiety. 
Mental health will be assessed by the Patient-Reported Outcomes Measurement Information 
System which looks at physical function, anxiety, depression, fatigue, sleep disturbance, pain, 
and ability to participate in social roles. The hope of this clinical trial is to determine whether 
stem cell therapies work to treat osteoarthritis and also which type of stem cell works best. The 
biggest strength of this clinical trial when it is complete will be that it was randomized unlike 
previous trials for stem cell therapy. The study also utilized participants with varying levels of 
osteoarthritis, so hopefully there will be different grades in each group to determine if one type 
of stem cell has more of an effect on a specific grade of osteoarthritis.  
 These case studies can yield some new conclusions while others are still left to be 
determined. The clinical trial under the Japanese Regenerative Medicine Act is important 
because it is the first trial to be supported by the government. It also yields results to show the 
medical community that stem cell therapy does decrease pain for those struggling with advanced 
osteoarthritis. Both the clinical trial done in Australia and the one done in Canada looked at 
dosage of stem cells which builds on the previous clinical trial. The Australian clinical trail 
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found that the best intervention in their study was the two injections 6 months apart for Grade II 
to Grade III osteoarthritis. The Canadian clinical trial concluded that the best intervention in their 
trial was the highest dose of stem cells, 50 million cells, for severe osteoarthritis (Grades III to 
IV). Both studies concluded that the stem cells did not fully heal the knee joint, but instead seem 
to take a more supportive role to assist the cells to decrease inflammation and limit pain. Lastly, 
the new clinical trial starting in the United States will hopefully yield results as to which stem 
cells are most effective for treating osteoarthritis in the knee.  
Cost 
Currently, if an individual wanted to receive stem cell therapy for osteoarthritis in the 
United States, the individual would apply to be a candidate at one of the stem cell clinics around 
the country (Figure 5). Treatments at the stem cell clinics vary as there is no standard treatment 
right now. For example, a clinic in Panama requires a 4-day treatment which includes a physical 
examination and blood testing followed by 3 intravenous injections of mesenchymal stem cells 
and intracellular injections if needed (Riordan 2017). This is very different from a clinic in 
Boston which considers the treatment an outpatient treatment as it only takes a few hours after 
the stem cells have been harvested and says the patient can walk within 24 hours (Boston Stem 
Cell Center, 2019). Stem cell therapy is not currently covered by insurance in the United States 
because it is not approved by the FDA, though it is in the clinical trial phase now, which is the 
last step before potential approval (FDA, 2019). Out-of-pocket costs often determine whether an 
individual can try a new medical technology. When using a stimulated patient of a 57-year-old 
male, the average cost for the 273 clinics which offer stem cell therapy was $5,156 (Piuzzi et al, 
2018). The range of costs was between $1,150 to $12,000 for clinics which provided same day 
unilateral stem cell knee injection. The average clinical efficacy was 82.2% with a range of 55% 
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to 100% (Piuzzi et al, 2018). If stem cells proved to be effective for treating a certain stage of 
osteoarthritis and if the effects were long term, then stem cell therapy would be more cost 
efficient than a total knee replacement.  
Side Effects/Concerns 
 Unfortunately, there are some potential risks associated with stem cell therapy for 
osteoarthritis. One of the major problems is that these stem cells are often cultured in vitro. In 
vitro culture can modify cellular characteristics which could form harmful viruses. There is 
currently no standardization, so quality of stem cell preparations varies greatly between suppliers 
increasing the risk of modified stem cells being used (van der Kraan, 2013). The second risk is a 
risk of unwanted tissue formation. A rabbit study using adipose-derived mesenchymal stem cells 
showed that several weeks after the injection, the mesenchymal stem cells were found both in the 
affected joint but also in other locations such as the thymus and gastrointestinal tract (van der 
Kraan, 2013). It is a fear that the migration of these cells to other locations of the body could 
result in unwanted calcifications at sensitive sites in the body which would lead to severe 
medical complications such as bone formation in the heart. A severe complication of using 
mesenchymal stem cells is that mesenchymal stem cells migrate towards tumor sites already in 
the body. Mesenchymal stem cells have been shown to support tumor invasion and metastasis 
(van der Kraan, 2013). It is a fear that the mesenchymal stem cells would become a source of 
nutrients for cancer cells to grow with, though, so far this appears to be an uncommon 
phenomenon in humans (van der Kraan, 2013). This aspect of safety is important for the FDA 






 Osteoarthritis is the most common joint disease in our society due to the rising elderly 
and obese populations. Individuals who suffer from osteoarthritis face crippling joint pain due to 
degradation of the cartilage in their joints. There is currently no cure for osteoarthritis. There are 
several temporary treatments such as anti-inflammatory medications or total knee replacements 
for those at the end stages of the disease. These treatments each have shortcomings, however, 
that make them less than ideal. Medications have dangerous side effects, so individuals cannot 
remain on them forever. A total knee replacement does fix the knee joint, but it also limits 
mobility. Most individuals cannot return to sport after a total knee replacement meaning that 
usually only individuals over 60 years old opt for this treatment. There are many individuals 
under 60 years old who need treatment who fall into this treatment gap. These individuals have 
very limited options. These individuals are the most important reason that stem cell therapies for 
osteoarthritis need to be further discussed. Stem cell therapy may allow individuals to continue 
to lead active lifestyles because the joint could be repaired.  
 So far stem cell therapy does not yield conclusive results as to if it is more beneficial than 
a total knee replacement for everyone. Not all stem cell therapy being offered today is beneficial 
for all patients. In fact, some treatments can be harmful to individuals seeking treatment. The 
FDA warns individuals to ask questions before receiving treatment such as whether the treatment 
is FDA approved or if it is being studied under an Investigational New Drug Application which 
is a clinical trial submitted to the FDA (FDA, 2019). The FDA also warns about therapies 
approved in other countries. It is imperative that the individual read the countries’ policies and 
ask questions to ensure that the treatment is safe (FDA, 2019).  
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 Warnings aside, stem cell therapy does appear to be a promising solution for the future. 
To start, there are no ethical issues because the stem cells come from within the individual- 
whether it be bone marrow or adipose tissue. This is important because for a long time the only 
stem cells being used for treatment were from an (unborn) fetus. Second, if stem cell therapy was 
approved and insurance covered part of the treatment, stem cell therapy would be very cost 
efficient. The procedure itself is between $37,000 to $44,000 cheaper than a total knee 
replacement (Table 1). Stem cell therapy, according to current studies, appears to also involve 
less rehabilitation care after the procedure. The stem cell therapy required about four weeks of 
quadriceps exercises while a total knee replacement requires about four months of physical 
therapy. The only drawback is that current evidence seemingly concludes that stem cell therapy 
might be more beneficial for mid-stage osteoarthritis rather than end-stage osteoarthritis like a 
total knee replacement. Future work should follow those who have had successful stem cell 
therapy for mid-stage osteoarthritis to determine how long the treatment works or if an individual 
would need a total knee replacement later in life anyway. It would also be useful to find a dosage 
of stem cells that are the best for the treatment to be effective. This is important to standardize 
the treatment, so it would more easily be approved by the FDA.  
 With these findings, Julia and Henry still have decisions to make about what to do about 
their osteoarthritis. Julia is a younger adult who still wants to remain active. She is also young 
enough that she might outlive a knee replacement. At her age, Julia does not have Grade IV 
osteoarthritis, but rather, she has a Grade II or III osteoarthritis diagnosis. Julia would benefit 
most from the stem cell treatment. Julia is healthy besides her osteoarthritis, so she has no 
precursors for not being able to receive the treatment. Her main problem is the increased pain 
that keeps her from being active. Pain is what the stem cells have been proven to decrease in 
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every case study. With stem cell therapy, Julia could be back to being active with little knee pain 
a few weeks after treatment opposed to waiting almost a year after a knee replacement. My 
advisement would be for Julia to try stem cell therapy from a reputable stem cell clinic which she 
can determine by asking the FDA.  
Henry is a different case than Julia. Henry is an older adult who is also overweight. 
Henry has not been active for 20 years. Henry has developed ulcers previously from taking anti-
inflammatory medications. Henry also has Grade IV osteoarthritis. The stem cell therapy has not 
proven to be as effective for the later stages of osteoarthritis because the stem cells do not do the 
healing of the joint themselves. The recovery for Henry would not be easy, but I would suggest 
him receiving a knee replacement. He will most likely not outlive the knee replacement, and it is 
a proven treatment. His weight is still a lot of added pressure to a knee joint, so the stem cells 
might not be as effective for relieving pain. Henry would have to be diligent and go to his 
physical therapy to regain as much knee movement and function as possible. It would not matter 
to Henry as much if he is unable to run or participate in sport again. He would potentially start 















Figure 1: Comparison of Knee Joints: The left image shows a normal knee joint. Notice the 
coverage of articular cartilage over the entire surface of the femoral condyles (lower projections 
of the femur bone). There is a gap between the femur and tibia in the healthy joint. The right 
image shows a knee joint affected by osteoarthritis. Notice the articular cartilage is broken and 
does not cover the femoral condyles. There is no joint gap, so the bones grind together. There is 













Figure 2: Kellgren-Lawrence Osteoarthritis Scale: The image shows the progression from a 
normal knee joint on the left to a severely affected knee joint on the right. Notice the change in 
cartilage between each knee. The leftmost picture shows an intact cartilage that surrounds the 
whole joint to cushion the bones. The second image shows a slight narrowing of the joint space 
as well as the development of osteocytes. The third image shows cartilage breaking down and 
cracking as it becomes thinner. In the fourth image, there is very little cartilage remaining and 












Figure 3: Global Western Ontario and McMaster Universities Arthritis Index (WOMAC) score. 
There was an improvement from baseline for both the one injection and two injection group. The 
baseline for one injection was 59 and it increased to 84 while the baseline for two injection was 
54 and it increased to 87. An increase in score insinuates less pain and stiffness of the knee. 

















Figure 4: Patient Reported Knee Injury and Osteoarthritis Outcome Score (KIOOS) and Western 
Ontario and McMaster Universities Index score (WOMAC). (A): The WOMAC score is on the 
left divided into its 3 subcategories- Function, Stiffness, and Pain. The KIOOS score is on the 
right divided into its 5 subcategories- Activities of Daily Living, Pain, Symptoms, Sports, and 
Quality of Life. (B): The breakdown of each subcategory to show how participants in each 
injection dosage responded. The dotted line is the line of clinical significance which is an 
increase of 10. The green line is the 1 million cell dosage. The blue line is the 10 million cell 












Cost Total Knee Replacement Stem Cell Therapy 
Procedure $49,500 $5,156* 
Inpatient $7,500 N/A 
Other  PT, follow-up, loss of 




Table 1: Cost Comparison of Total Knee Replacement and Stem Cell Therapy. The total knee 
replacement will cost about $57,000 before physical therapy, follow-up appointments, and loss 
wages because the individual cannot work. Stem cell therapy costs an average of 5,156, but there 
is a range of $1,150 to $12,000 depending on the clinic one chooses to go to. There also could be 
inpatient charges if the clinic is not an outpatient treatment facility. (* denotes that cost is not set 





















Figure 5: Patient results after stem cell therapy. This patient, who received treatment from a 
stem cell clinic in Indiana, shows increased joint space after stem cell therapy. The left image 
shows the knee before the stem cell therapy. The joint space was very limited. The right image 
shows the knee 8 months after stem cell therapy. The joint space increased drastically. The knee 
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